Insulet Corp
NASDAQ:PODD
Net Margin
Insulet Corp
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Insulet Corp
NASDAQ:PODD
|
18.9B USD |
20%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
228.5B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
180.6B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
147.4B USD |
11%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
144B USD |
13%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
114B USD |
13%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
65.7B USD |
8%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
56.1B EUR |
9%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
42.4B USD |
77%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
273.8B CNY |
33%
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
36.3B USD |
10%
|
Insulet Corp
Glance View
Insulet Corporation has carved out a significant niche in the medical device industry, distinguishing itself through its innovative approach to diabetes management. The company is best known for its Omnipod Insulin Management System, a discreet, tubeless insulin pump that provides a solution for individuals with diabetes seeking an alternative to traditional insulin delivery methods. Unlike conventional pumps that require cumbersome tubes and significant patient involvement, the Omnipod system offers ease and convenience, allowing users more freedom and flexibility in their daily lives. The system operates via a small wearable pod that delivers insulin over several days, which users control remotely, removing much of the hassle associated with managing diabetes. Insulet generates revenue by selling these pods and the associated Personal Diabetes Manager (PDM) devices, which together comprise the entire system. Customers typically purchase pods on a recurring basis, similar to a subscription model, which creates a steady stream of revenue for the company. The business model emphasizes continuous growth by expanding its user base and improving its technology to remain at the forefront of patient-centric diabetes care. Insulet's strategic focus on the needs of its users and commitment to refining their health technology has enabled it to build a sustainable business that addresses a critical healthcare challenge while also delivering consistent financial performance.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Insulet Corp's most recent financial statements, the company has Net Margin of 20.2%.
You don't have any saved screeners yet